Biovica International Management

Management criteria checks 2/4

Biovica International's CEO is Anders Rylander, appointed in Jan 2011, has a tenure of 13.33 years. directly owns 6.11% of the company’s shares, worth €717.26K. The average tenure of the management team and the board of directors is 2.8 years and 8.3 years respectively.

Key information

Anders Rylander

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	13.3yrs
CEO ownership	6.1%
Management average tenure	2.8yrs
Board average tenure	8.3yrs

Recent management updates

Recent updates

CEO

Anders Rylander (53 yo)

13.3yrs

Tenure

Mr. Anders Rylander serves as Chief Executive Officer of Biovica International AB (publ) since 2010. Mr. Rylander is the Founder of Arinvest and Co-Founder of Axholmen. He has been a Management Consultant...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Anders Rylander	CEO & Director	13.3yrs	no data	6.11% SEK 717.3k
Anders Moren	Chief Financial Officer	1.3yrs	no data	0.027% SEK 3.2k
Hanna Ritzén	Chief Operating Officer	1.3yrs	no data	0.0037% SEK 433.0
Henrik Winther	Senior Vice President of Business Development	4.3yrs	no data	0.038% SEK 4.5k
Warren Cresswell	President of Americas	2.8yrs	no data	no data
Mattias Bergqvist	Vice President of Clinical Development	no data	no data	no data
Helle Fisker	Vice President of Commercial	no data	no data	0.026% SEK 3.0k

2.8yrs

Average Tenure

54yo

Average Age

Experienced Management: 9II's management team is considered experienced (2.8 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Anders Rylander	CEO & Director	14.3yrs	no data	6.11% SEK 717.3k
Lars Holmqvist	Independent Chairman of the Board	5.2yrs	kr480.00k	0.78% SEK 92.1k
Annika Berg	Independent Director	4.3yrs	kr200.00k	0.030% SEK 3.5k
Maria Holmlund	Independent Director	8.3yrs	kr250.00k	0.019% SEK 2.2k
Jarl Jungnelius	Independent Director	10.3yrs	kr200.00k	no data
Jesper Soderqvist	Independent Director	11.3yrs	kr230.00k	0.12% SEK 14.3k
Marie-Louise Fjallskog	Independent Director	4.3yrs	kr200.00k	no data

8.3yrs

Average Tenure

60yo

Average Age

Experienced Board: 9II's board of directors are considered experienced (8.3 years average tenure).

Biovica International Management

Management criteria checks 2/4

Key information

Recent management updates

Biovica International AB (publ), Annual General Meeting, Sep 17, 2024

Insufficient new directors

Biovica International AB (publ) Appoints Anders Morén as CFO

Biovica International AB (Publ) Announces Resignation of Cecilia Driving as deputy CEO, Effective December 31, 2022

Biovica International AB Announces Nomination Committee Appointments

Independent Chairman of the Board recently bought €61k worth of stock

Recent updates

New minor risk - Profitability

Forecast breakeven date pushed back to 2027

Biovica International AB (Publ) Announces Divitum® Tka in Observational Trial

Biovica International AB (publ) to Report Q4, 2025 Results on Jun 19, 2025

Biovica International AB (publ), Annual General Meeting, Sep 17, 2024

Biovica Announces Interventional DiviTum TKa Trial Launches at Washington University

Third quarter 2024 earnings released: kr0.43 loss per share (vs kr0.62 loss in 3Q 2023)

Biovica International AB (publ) has completed a Composite Units Offering in the amount of SEK 119.385023 million.

Second quarter 2024 earnings released: kr0.56 loss per share (vs kr0.81 loss in 2Q 2023)

Biovica Receives Final Pricing Decision for DiviTum TKa Test by Medicare

New major risk - Market cap size

New major risk - Financial position

First quarter 2024 earnings released: kr0.70 loss per share (vs kr0.74 loss in 1Q 2023)

Biovica Announces the Start of a DiviTum(R) TKa Clinical Trial

Biovica International Achieves PLA code for Medicare

New major risk - Share price stability

Full year 2023 earnings released: kr2.42 loss per share (vs kr2.11 loss in FY 2022)

Biovica International AB (publ) Announces A Poster with DivTum® TKa Results from the SWOG Study S0226

Third quarter 2023 earnings released

Biovica International Receives Clia Certification

Biovica International Announces DiviTum(R) TKa Clinical Validation Data Published in Biomarkers

Insufficient new directors

Second quarter 2023 earnings released

Biovica International AB (publ) Appoints Anders Morén as CFO

Biovica Submits CLIA Lab Application for DiviTum(R)TKa Launch

First quarter 2023 earnings released

Biovica International AB (publ) Receives FDA Approval for DiviTum®TKa

Biovica International AB (Publ) Announces Resignation of Cecilia Driving as deputy CEO, Effective December 31, 2022

Full year 2022 earnings released: kr2.11 loss per share (vs kr1.39 loss in FY 2021)

Biovica International Announces DiviTumTKa Predicts Clinical Outcome of Patients in BioitaLEE Study

Third quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Biovica International AB Announces Nomination Committee Appointments

Biovica Announces Positive DiviTum®TKa Results from the European Multicenter Study PYTHIA Have Been Published in the Highly Ranked Peer-Reviewed Scientific Journal European Journal of Cancer

Now 20% undervalued after recent price drop

Now 22% undervalued after recent price drop

Second quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Second quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Biovica announces the start of the TK IMPACT trial at Washington University of St Louis

Forecast to breakeven in 2023

Forecast to breakeven in 2024

Forecast to breakeven in 2024

Independent Chairman of the Board recently bought €61k worth of stock

Forecast to breakeven in 2024

Full year 2021 earnings released: kr1.39 loss per share (vs kr1.29 loss in FY 2020)

Biovica’S Divitumtka Shows Strong Capabilities in Malignant Melanoma

Biovica International AB (publ), Annual General Meeting, Aug 31, 2021

FDA Resumes Review of Biovica International's Divitum®TKA Submission

CEO

Tenure

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age